{
  "id": 15019898,
  "title": "Imaging-based modalities compared for identifying at-risk MASH",
  "url": "https://urgent.news/2026/10/16/imaging-based-modalities-compared-for-identifying-at-risk-mash",
  "topic": "science",
  "section": "Science",
  "published": "2026-10-16T18:40:01.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-10-imaging-based-modalities-mash.html"
  },
  "original_language": "en",
  "account": "A study published in the October issue of the American Journal of Gastroenterology has found that FibroScan-aspartate aminotransferase (FAST) has the highest sensitivity for ruling out at-risk metabolic dysfunction-associated steatohepatitis (MASH). Researchers Shyna Zhuoying Gunalan and colleagues conducted a systematic review of 20 studies involving 9,480 participants to evaluate the diagnostic performance of imaging-based technologies for at-risk MASH. FAST demonstrated a sensitivity of 87.1% and a specificity of 56.7% in ruling out at-risk MASH, outperforming other diagnostic methods. Magnetic resonance elastography plus fibrosis-4 had a sensitivity of 81.2% and a specificity of 60.6%, while FAST also showed the best performance in head-to-head analyses. Despite FAST's superior sensitivity, magnetic resonance-based technologies still provide strong evidence for identifying at-risk MASH.",
  "summary": "FibroScan-aspartate aminotransferase (FAST) demonstrated the highest sensitivity for ruling out at-risk metabolic dysfunction-associated steatohepatitis (MASH), according to a study published in the October issue of the American Journal of Gastroenterology.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}